Neurotrope (NASDAQ:NTRP) was downgraded by equities researchers at ValuEngine from a “buy” rating to a “hold” rating in a research report issued on Thursday.

Separately, Maxim Group reissued a “buy” rating and issued a $16.00 price objective on shares of Neurotrope in a research report on Tuesday, February 5th.

Shares of NTRP stock opened at $5.11 on Thursday. Neurotrope has a 12 month low of $3.33 and a 12 month high of $11.93.

Neurotrope (NASDAQ:NTRP) last announced its quarterly earnings data on Monday, March 11th. The company reported ($0.47) EPS for the quarter.

Hedge funds have recently made changes to their positions in the company. Raymond James & Associates bought a new stake in shares of Neurotrope in the fourth quarter worth $42,000. Eaton Vance Management bought a new stake in Neurotrope during the fourth quarter worth $164,000. Finally, Renaissance Technologies LLC raised its position in Neurotrope by 72.4% during the third quarter. Renaissance Technologies LLC now owns 50,000 shares of the company’s stock worth $441,000 after acquiring an additional 21,000 shares in the last quarter. 10.72% of the stock is currently owned by institutional investors and hedge funds.

About Neurotrope

Neurotrope, Inc, a biopharmaceutical company, focuses on the development of a product platform for the treatment of Alzheimer's disease (AD). Its lead product candidate is bryostatin, a natural product isolated from a marine invertebrate organism, a bryozoan called Bugula neritina. The company also develops bryostatin for other neurodegenerative or cognitive diseases and dysfunctions, such as Fragile X and Niemann-Pick Type C.

Read More: Cost of Equity

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Neurotrope Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Neurotrope and related companies with MarketBeat.com's FREE daily email newsletter.